SCHEMBL17239604

SCHEMBL17239604

COC(=O)c1cc(-c2cccc(CC(F)F)n2)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 6/20 0.54
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MEN1 O00255 3/20 0.41
LMNA P02545 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PFKFB3 Q16875 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
TRPV3 Q8NET8 1/20 0.40
NR4A2 P43354 1/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17239589 0.85 NTRK1 (0.57) NTRK1ALDH1A1
SCHEMBL17239563 0.78 CNR2 (0.45) NTRK1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL17239627 0.78 NTRK1 (0.55) NTRK1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL17239418 0.77 LMNA (0.44) NTRK1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL1786548 0.77 CNR1 (0.53) NTRK1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL17239477 0.77 SMN1; SMN2 (0.41) NTRK1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL1788339 0.74 P2RX7 (0.58) NTRK1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL17186883 0.72 SMN1; SMN2 (0.49) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL4436292 0.70 NOTUM (0.57) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL4471814 0.69 P2RX7 (0.57) MAPTSMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
WO-2015170218-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2015-11-12 WO disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS TPM3, MUSK, TPM4 NTRK1 8/4885MAPT 330/4885SMN1; SMN2 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.